Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Atlassian (TEAM) upgraded to Buy from Neutral at Goldman Sachs with Heather Bellini saying consensus billings expectations for Q4 of $361M, or up 30% year-over-year, appear conservative. 2. Match Group (MTCH) upgraded to Neutral from Sell at Goldman Sachs with 3ith analyst Michael Ng stating that the positive stock reaction to Match's in-line Q1 revenue and EBITDA results illustrate the market is more focused on the longer-term investment thesis. 3. Protagonist Therapeutics (PTGX) upgraded to Buy from Hold at Stifel with analyst Adam Walsh saying yhe expansion of the deal between Protagonist and Janssen for PTG-200 and other IL-23 receptor antagonists brings large pharma validation to the former's oral peptide platform. 4. Penn National (PENN) upgraded to Buy from Neutral at BofA/Merrill with analyst Shaun Kelley stating that its core consumer remains stable and he believes catalysts such as the relaunch of MyChoice and sports betting are being underappreciated by investors. 5. Ferrari (RACE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Adam Jonas noting the company's better than expected Q1 results and saying he has higher conviction in the company's strategy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,
click here.